Loading...
•
Sep 30, 2024
McKesson Q2 2025 Earnings Report
McKesson reported record revenue and adjusted earnings growth, driven by strong performance in the U.S. Pharmaceutical segment.
Key Takeaways
McKesson Corporation announced strong second-quarter results, with a 21% increase in consolidated revenues to $93.7 billion and a 13% increase in Adjusted Earnings per Diluted Share to $7.07. The company also raised its full-year adjusted EPS guidance to $32.40 to $33.00.
Consolidated revenues increased by 21% to $93.7 billion.
Adjusted Earnings per Diluted Share grew by 13% to $7.07.
Full-year Adjusted Earnings per Diluted Share guidance raised to $32.40 to $33.00.
Agreement announced to acquire a controlling interest in Florida Cancer Specialists & Research Institute LLC's Core Ventures.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson is raising and narrowing fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.40 to $33.00 from the previous range of $31.75 to $32.55.
Positive Outlook
- Fiscal 2025 Adjusted Earnings per Diluted Share guidance range raised to $32.40 to $33.00.
- Fiscal 2025 Adjusted Earnings per Diluted Share guidance range indicates 18% to 20% growth compared to prior year.
- Full year share repurchases target raised from $2.8 billion to $3.2 billion.
- Fiscal 2025 Adjusted Earnings per Diluted Share guidance includes $0.53 related to year-to-date gains associated with McKesson Ventures' equity investments.
- Company remains confident in its ability to deliver against its fiscal 2025 outlook, which is above the long-term targets previously provided.
Challenges Ahead
- McKesson does not provide forward-looking guidance on a GAAP basis.
- McKesson cannot reasonably forecast LIFO inventory-related adjustments.
- McKesson cannot reasonably forecast certain litigation loss and gain contingencies.
- McKesson cannot reasonably forecast restructuring, impairment and related charges.
- McKesson cannot reasonably forecast other adjustments, which are difficult to predict and estimate.
Revenue & Expenses
Visualization of income flow from segment revenue to net income